Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, phase 2, long-term safety study of inhaled insulin: an up to four-year extension of therapy in subjects with type 1 or type 2 diabetes mellitus participating in extension protocols 217-102, 103, or 104.

Next Previous
X
Search
Trial Profile

An open-label, phase 2, long-term safety study of inhaled insulin: an up to four-year extension of therapy in subjects with type 1 or type 2 diabetes mellitus participating in extension protocols 217-102, 103, or 104.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 10 Nov 2009 Planned number of patients changed from 70 to 173 as reported by ClinicalTrials.gov.
    • 19 Dec 2007 Status changed from in progress to discontinued. Clinicaltrials.gov states "Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons."
    • 26 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top